Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2008

01.09.2008 | Original Article

Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas

verfasst von: T. Clark Gamblin, Merrill J. Egorin, Eleanor G. Zuhowski, Theodore F. Lagattuta, Laurie L. Herscher, Angelo Russo, Steven K. Libutti, H. Richard Alexander, Robert L. Dedrick, David L. Bartlett

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

The pyrimidine analogue gemcitabine (2′, 2′-difluorodeoxycitidine, dFdC) is active against pancreatic cancer, and its high clearance (CLtb) and low incidence of local toxicity make it an excellent candidate for evaluation as intraperitoneal (IP) therapy. We designed a dosing schema that used multiple sequential exchanges of a peritoneal dialysate containing dFdC in an effort to produce prolonged IP dFdC exposure.

Methods

As part of a study involving multi-modality therapy for advanced pancreatic adenocarcinoma, patients were treated with four 6-h IP dwells of dFdC (50 mg/m2 in 2 l) over a 24-h period. A second 24-h cycle of IP dFdC therapy was repeated 1 week later. Each exchange of dialysate contained 50 mg/m2 dFdC in 2 l of commercial 1.5% dextrose dialysis solution. Plasma and peritoneal fluid were analyzed by HPLC to determine concentrations of dFdC and its inactive metabolite 2′, 2′ difluorodeoxyuridine (dFdU). Clinical data were recorded to note drug toxicity and response.

Results

Nine patients underwent IP dFdC therapy, and eight were able to receive two cycles. There were no recorded significant toxicities. Low plasma dFdC concentrations (<1 μg/ml) were present transiently in seven of nine patients, and dFdC was not detectable in the plasma of the other two. Plasma dFdU concentrations were low but increased gradually until 12 h and then declined little if any. IP dFdC concentrations declined rapidly, and dFdC was seldom measurable prior to administration of the next scheduled 6-h dwell. dFdU concentrations in peritoneal fluid were very low (<0.5 μg/ml) throughout treatment. The mean area under the concentration versus time curve (AUC) for dFdC in peritoneal fluid was 182 μg/ml × h, which was approximately 70× the AUC of dFdC reported in the ascites of a patient undergoing systemic dFdC therapy.

Conclusions

IP dFdC was well tolerated, and no significant toxicities were noted. The rapid decrease in peritoneal dFdC concentrations and low concentrations of IP dFdU imply almost total absorption of IP-administered dFdC. Little, if any, dFdC could be detected in plasma, but the steady-state plasma dFdU concentrations also imply absorption and inactivation of virtually all IP-administered dFdC. These findings are consistent with the known high CLtb and low incidence of local toxicity of dFdC and argue for its further evaluation as a drug for IP therapy.
Literatur
1.
Zurück zum Zitat Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMed Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMed
2.
Zurück zum Zitat Dedrick RL (1986) Interspecies scaling of regional drug delivery. J Pharm Sci 75(11):1047–1052PubMedCrossRef Dedrick RL (1986) Interspecies scaling of regional drug delivery. J Pharm Sci 75(11):1047–1052PubMedCrossRef
3.
Zurück zum Zitat Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3):1–6PubMed Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3):1–6PubMed
4.
Zurück zum Zitat Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11PubMed Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11PubMed
5.
Zurück zum Zitat Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zuhowski EG, Plunkett W, Zamboni WC (2000) Pharmacokinetics of gemcitabine and 2′, 2′-difluorodexoyrindine in patient with ascites. Pharmacotherapy 20(10):1204–1207PubMedCrossRef Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zuhowski EG, Plunkett W, Zamboni WC (2000) Pharmacokinetics of gemcitabine and 2′, 2′-difluorodexoyrindine in patient with ascites. Pharmacotherapy 20(10):1204–1207PubMedCrossRef
6.
Zurück zum Zitat Fossella FV, Lippman SM, Shin DM et al. (1997) Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small cell lung cancer. J Clin Oncol 15(1):310–316PubMed Fossella FV, Lippman SM, Shin DM et al. (1997) Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small cell lung cancer. J Clin Oncol 15(1):310–316PubMed
7.
Zurück zum Zitat Gastointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80(10):751–755CrossRef Gastointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80(10):751–755CrossRef
8.
Zurück zum Zitat Green MR (1996) Gemcitabine safety overview. Semin Oncol 23(5):32–35PubMed Green MR (1996) Gemcitabine safety overview. Semin Oncol 23(5):32–35PubMed
9.
Zurück zum Zitat Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413PubMed Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413PubMed
10.
Zurück zum Zitat Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′- difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine. Cancer Res 48(14):4024–4031PubMed Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′- difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine. Cancer Res 48(14):4024–4031PubMed
11.
Zurück zum Zitat Heinemann V, Xu Y, Chubb S, Sen A, Hertel LW, Grindley GB, Plunkett W (1990) Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2′, 2′-difluorodeoxy-cytidine. Mol Pharmacol 38(4):567–572PubMed Heinemann V, Xu Y, Chubb S, Sen A, Hertel LW, Grindley GB, Plunkett W (1990) Inhibition of ribonucleotide reductase in CCRF-CEM cells by 2′, 2′-difluorodeoxy-cytidine. Mol Pharmacol 38(4):567–572PubMed
12.
Zurück zum Zitat Hertel LW, Boder GB, Kroin JS, Rinzel SM et al (1990) Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxyctidine). Cancer Res 50(14):4417–4422PubMed Hertel LW, Boder GB, Kroin JS, Rinzel SM et al (1990) Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxyctidine). Cancer Res 50(14):4417–4422PubMed
13.
Zurück zum Zitat Jemal A, Tiwari RC, Ghafoor A et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMedCrossRef Jemal A, Tiwari RC, Ghafoor A et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMedCrossRef
14.
Zurück zum Zitat Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintence 5-fluoruracil––an Eastern Cooperative Oncology Study Group. J Clin Oncol 3:373–378PubMed Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintence 5-fluoruracil––an Eastern Cooperative Oncology Study Group. J Clin Oncol 3:373–378PubMed
15.
Zurück zum Zitat Lund B, Kristjansen PE, Hansen HH (1993) Clinical and preclinical activity of 2′, 2′-difuorodeoxycytidine (gemcitabine). Cancer Treat Rev 19(1):45–55PubMedCrossRef Lund B, Kristjansen PE, Hansen HH (1993) Clinical and preclinical activity of 2′, 2′-difuorodeoxycytidine (gemcitabine). Cancer Treat Rev 19(1):45–55PubMedCrossRef
16.
Zurück zum Zitat Macchia G, Valentini V, Mattiucci GC et al. (2007) Preoperative chemoradiation and intra-operative radiotherapy for pancreatic carcinoma. Tumori 93(1):53–60PubMed Macchia G, Valentini V, Mattiucci GC et al. (2007) Preoperative chemoradiation and intra-operative radiotherapy for pancreatic carcinoma. Tumori 93(1):53–60PubMed
17.
Zurück zum Zitat Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally resectable pancreatic carcinoma: a randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710PubMedCrossRef Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally resectable pancreatic carcinoma: a randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710PubMedCrossRef
18.
Zurück zum Zitat Moore MJ, Tannock IF, Ernst DS et al. (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15(12):3441–3445PubMed Moore MJ, Tannock IF, Ernst DS et al. (1997) Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15(12):3441–3445PubMed
19.
Zurück zum Zitat Murphy JD, Adusumilli S, Griffith KA et al. (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68(3):801–808PubMed Murphy JD, Adusumilli S, Griffith KA et al. (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68(3):801–808PubMed
20.
Zurück zum Zitat Pestieau SR, Stuart OA, Chang D et al. (1998) Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 84(6):706–711PubMed Pestieau SR, Stuart OA, Chang D et al. (1998) Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori 84(6):706–711PubMed
21.
Zurück zum Zitat Regine WF, Abrams RA (2006) Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol 33(6):S10–S13PubMedCrossRef Regine WF, Abrams RA (2006) Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol 33(6):S10–S13PubMedCrossRef
22.
Zurück zum Zitat Ridwelski K, Meyer F, Hribaschek A et al. (2002) Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurrence of peritoneal carcinomatosis. J Surg Oncol 79:10–16PubMedCrossRef Ridwelski K, Meyer F, Hribaschek A et al. (2002) Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurrence of peritoneal carcinomatosis. J Surg Oncol 79:10–16PubMedCrossRef
24.
Zurück zum Zitat Sabbatini P, Aghajanian C, Leitao M et al. (2004) Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. Clin Cancer Res 10(9):2962–2967PubMedCrossRef Sabbatini P, Aghajanian C, Leitao M et al. (2004) Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. Clin Cancer Res 10(9):2962–2967PubMedCrossRef
25.
Zurück zum Zitat Schultz RM, Merriman RL, Toth JE, Zimmermann JE et al. (1993) Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5(6–7):223–228PubMed Schultz RM, Merriman RL, Toth JE, Zimmermann JE et al. (1993) Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5(6–7):223–228PubMed
26.
Zurück zum Zitat Shaib YH, Davila JA, Naumann C, El-Serag H (2007) The impact of curative intent surgery on the survival of pancreatic cancer patients: A US population-based study. Am J Gastroenterol 102:1–6CrossRef Shaib YH, Davila JA, Naumann C, El-Serag H (2007) The impact of curative intent surgery on the survival of pancreatic cancer patients: A US population-based study. Am J Gastroenterol 102:1–6CrossRef
27.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL et al (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579PubMedCrossRef Sohn TA, Yeo CJ, Cameron JL et al (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579PubMedCrossRef
28.
Zurück zum Zitat Stadler WM, Kuzel T, Roth B et al. (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15(11):3394–3398PubMed Stadler WM, Kuzel T, Roth B et al. (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15(11):3394–3398PubMed
29.
Zurück zum Zitat Storniolo AM, Allerheiligen SR, Pearce HL (1997) Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24:S7-2–S7-7 Storniolo AM, Allerheiligen SR, Pearce HL (1997) Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24:S7-2–S7-7
30.
Zurück zum Zitat Sultana A, Tudur Smith C, Cunningham D et al. (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96(8):1183–1190PubMedCrossRef Sultana A, Tudur Smith C, Cunningham D et al. (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96(8):1183–1190PubMedCrossRef
31.
Zurück zum Zitat Toschi L, Finocchiaro G, Bartolini S et al. (2005) Role of gemcitabine in cancer therapy. Future Oncol 1(1):7–17PubMedCrossRef Toschi L, Finocchiaro G, Bartolini S et al. (2005) Role of gemcitabine in cancer therapy. Future Oncol 1(1):7–17PubMedCrossRef
32.
Zurück zum Zitat Vennok AP, Egorin MJ, Rosner GL et al. (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18(14):2780–2787 Vennok AP, Egorin MJ, Rosner GL et al. (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 18(14):2780–2787
33.
Zurück zum Zitat Vyas VP, Rubin EH, Zamek R et al. (2000) Intraperitoneal gemcitabine: phase I study. Proc AACR 41:612 (Abstract) Vyas VP, Rubin EH, Zamek R et al. (2000) Intraperitoneal gemcitabine: phase I study. Proc AACR 41:612 (Abstract)
34.
Metadaten
Titel
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas
verfasst von
T. Clark Gamblin
Merrill J. Egorin
Eleanor G. Zuhowski
Theodore F. Lagattuta
Laurie L. Herscher
Angelo Russo
Steven K. Libutti
H. Richard Alexander
Robert L. Dedrick
David L. Bartlett
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2008
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-007-0647-9

Weitere Artikel der Ausgabe 4/2008

Cancer Chemotherapy and Pharmacology 4/2008 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.